publication venue for
- Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.. 24:60. 2023
- Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs.. 23:35. 2021
- Coating characterization by hyperspectroscopy and predictive dissolution models of tablets coated with blends of cellulose acetate and cellulose acetate phthalate.. 22:122. 2021
- Potential Application of USP Paddle and Basket Dissolution Methods in Discriminating for Portioned Moist Snuff and Snus Smokeless Tobacco Products.. 22:51. 2021
- Salt Engineering of Aripiprazole with Polycarboxylic Acids to Improve Physicochemical Properties.. 22:31. 2021
- Formulation Optimization of Selective Laser Sintering 3D-Printed Tablets of Clindamycin Palmitate Hydrochloride by Response Surface Methodology.. 21:232. 2020
- Effects of Diluents on Physical and Chemical Stability of Phenytoin and Phenytoin Sodium.. 21:104. 2020
- Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate.. 21:99. 2020
- Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion.. 20:230. 2019
- Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.. 20:166. 2019
- In Vitro Drug Transfer Due to Drug Retention in Human Epidermis Pretreated with Application of Marketed Estradiol Transdermal Systems.. 18:2131-2140. 2017
- Comparison of Univariate and Multivariate Models of C SSNMR and XRPD Techniques for Quantification of Nimodipine Polymorphs.. 16:1368-1376. 2015
- Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.. 15:601-611. 2014
- SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.. 15:472-482. 2014
- Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.. 15:772-780. 2014
- Nanomedicine scale-up technologies: feasibilities and challenges.. 15:1527-1534. 2014
- Development and validation of a HPLC method for dissolution and stability assay of liquid-filled cyclosporine capsule drug products.. 14:959-967. 2013
- Ion-pair chromatography for simultaneous analysis of ethionamide and pyrazinamide from their porous microparticles.. 14:1313-1320. 2013
- Improvement of physicochemical properties of an antiepileptic drug by salt engineering.. 13:793-801. 2012
- Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies.. 13:611-622. 2012
- Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide.. 12:693-704. 2011
- NIR spectroscopy applications in the development of a compacted multiparticulate system for modified release.. 12:262-278. 2011
- A QbD case study: Bayesian prediction of lyophilization cycle parameters.. 12:442-448. 2011
- Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium.. 11:1359-1367. 2010
- Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.. 11:818-825. 2010
- Difference in the lubrication efficiency of bovine and vegetable-derived magnesium stearate during tabletting.. 10:500-504. 2009
- Disintegration of highly soluble immediate release tablets: a surrogate for dissolution.. 10:495-499. 2009
- Comparative evaluation of flow for pharmaceutical powders and granules.. 9:250-258. 2008
- Formulation of anastrozole microparticles as biodegradable anticancer drug carriers.. 7:61-e46. 2006
- Characterization of 5-fluorouracil microspheres for colonic delivery.. 7:E47-e6. 2006
- Monitoring tablet surface roughness during the film coating process.. 7:E31-E6. 2006
- Response surface methodology for optimization and characterization of limonene-based coenzyme Q10 self-nanoemulsified capsule dosage form.. 5:e66-121. 2004
- Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system.. 3:E3-31. 2002